The DMR signature demonstrated robust applicability in predicting tumor progression. (A) Principal component analysis of 14-DMR signature patients under 120 samples with tumor progression (deep grey) or not (light grey). Circle color referred to the risk group. Tumor progression (B) and tumor recurrence (C) ROC curve of prognostic prediction using 14-DMR signature (blue), GS (purple), and tumor T stage (green). The AUC value of each curve and the statistical significance (*0.05, **0.01, ***0.001) of differences compared to the signature were summarized in the lower right corner of the plots.
Muheng Liao & co show that a DNA methylation signature outperformed traditional clinical markers in predicting prostate #cancer progression, offering improved risk assessment for treatment decisions in intermediate-risk patients. doi.org/10.1242/bio....
#ProstateCancer #DNAmethylation